A Pilot Phase 1, Randomized, Single-Dose, 6-Sequences, 3-Period, Crossover Bioavailability Study of MELT-100 (Midazolam and Ketamine Sublingual Tablet) and Intravenous Midazolam or Ketamine in Healthy Volunteers
Latest Information Update: 02 Nov 2021
At a glance
- Drugs Ketamine+midazolam (Primary) ; Ketamine; Midazolam
- Indications Sedation
- Focus Pharmacokinetics
- Acronyms MELT
- Sponsors Melt Pharmaceuticals
- 09 Feb 2021 Status changed from recruiting to completed, according to a Melt Pharmaceuticals media release..
- 09 Feb 2021 Results published in the Melt Pharmaceuticals media release.
- 29 Jul 2020 Status changed from not yet recruiting to recruiting, according to a Melt Pharmaceuticals media release.